A new study from the Department of Energy’s Pacific Northwest National Laboratory has revealed just how serious long-term alcohol use can be, especially when it leads to a life-threatening liver disease called alcohol-associated hepatitis.
This illness, caused by years of heavy drinking, is even more dangerous than better-known conditions like cirrhosis or fatty liver disease.
Alcohol-associated hepatitis usually develops in people who have been drinking large amounts of alcohol daily for more than 10 years—such as a six-pack of beer, a bottle of wine, or four shots of liquor per day.
Sadly, the disease has a high death rate: about 10% of patients die within one month of being diagnosed, and nearly 25% die within six months. These numbers show how deadly this condition really is.
To better understand what happens in the body during alcohol-associated hepatitis, researchers studied blood and tissue samples from 106 people.
Among them, 57 had alcohol-associated hepatitis, while the rest either had other liver conditions (like cirrhosis or nonalcoholic fatty liver disease) or were healthy. The team used a special technique called mass spectrometry to study more than 1,500 different proteins in their blood.
The findings were striking. The team discovered that in people with alcohol-associated hepatitis, about 100 specific proteins in the blood were significantly altered. These proteins are responsible for a wide range of important functions, including inflammation, immune response, blood clotting, and general liver function.
One of the key players identified was a molecule called HNF4A. This molecule helps control which genes are turned on or off in the liver, and it’s also involved in diseases like pancreatic cancer and diabetes.
In this study, HNF4A stood out because it seemed to be linked to the many disruptions happening inside the liver. The same types of protein changes seen in the blood also matched changes happening in the liver tissue itself.
This connection between changes in the blood and damage in the liver is important. It suggests that doctors could one day use a simple blood test to diagnose alcohol-associated hepatitis—something that is currently very difficult to do without more invasive methods. Such a test would be a breakthrough in catching the disease early, when treatment is more likely to help.
At the moment, the main treatment for alcohol-associated hepatitis is steroids, which aim to reduce inflammation. But these drugs also lower the immune system’s defenses, making patients more prone to infections. That’s why there’s a strong need to find safer and more effective ways to treat and monitor this condition.
The team, led by biochemist Jon Jacobs, is now studying whether these 100 protein markers could also help track how well patients respond to treatments over time. Their goal is to develop better tools for doctors to use—not just to detect the disease earlier, but to improve the odds of recovery.
This study, published in the American Journal of Pathology, also reminds us of the serious health risks of long-term heavy drinking. While moderate alcohol use may seem harmless to some, sustained overuse can quietly damage the liver until it’s too late.
If you’re focused on your health, this research is a reason to think twice about your drinking habits and talk with a doctor if you have concerns.
Other studies have also shown how certain lifestyle choices—like eating a low-carb diet or getting enough vitamin K—can support better health and reduce the risk of heart disease. In the future, discoveries like this one may lead to powerful new tools to prevent and treat serious conditions before they become deadly.
If you care about wellness, please read studies about how alcohol affects liver health and disease progression, and even one drink a day could still harm blood pressure health.
For more health information, please see studies that your age may decide whether alcohol is good or bad for you, and people over 40 need to prevent dangerous alcohol/drug interactions.
Copyright © 2025 Knowridge Science Report. All rights reserved.
